Page last updated: 2024-12-06

dioxohexahydrotriazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID33674
CHEMBL ID208992
SCHEMBL ID1411120
MeSH IDM0075168

Synonyms (37)

Synonym
nsc119749
1,5-triazinane-2,4-dione
nsc-119749
27032-78-6
dihydro-1,3,5-triazine-2,4(1h,3h)-dione
dioxohexahydrotriazine
nsc 119749
einecs 248-178-0
ccris 3441
5-azadihydrouracil
1,3,5-triazinane-2,4-dione
CHEMBL208992
FT-0694306
STK076465
A818861
2,4-dioxohexahydro-1,3,5-triazine
unii-8f9sny1m73
8f9sny1m73 ,
AKOS009075844
1,3,5-triazine-2,4(1h,3h)-dione,dihydro-
T3800
hexahydro-1,3,5-triazin-2,4-dione
YTFXKURWTLWPKK-UHFFFAOYSA-N
SCHEMBL1411120
DTXSID10181516
AS-64545
ckb 1130
s-triazine-2,4(1h,3h)-dione, dihydro-
1,3,5-triazine-2,4(1h,3h)-dione, dihydro-
triazinane-2,4-dione
5,6-dihydro-1,3,5-triazine-2,4(1h,3h)-dione
mfcd00085440
SB73467
T72202
CS-0215113
EN300-22343
Z147642476
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID264705Antiviral activity against TMV2006Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10
Discovery of bitriazolyl compounds as novel antiviral candidates for combating the tobacco mosaic virus.
AID1082995Antiviral activity against Tobacco mosaic virus (TMV) assessed as inhibition of viral growth at 500 ug/mL2012Journal of agricultural and food chemistry, Sep-05, Volume: 60, Issue:35
Design, synthesis, and antiviral activity evaluation of phenanthrene-based antofine derivatives.
AID1092029In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves exposed to 500 ug/mL for 20 min assessed as inhibition of viral growth measured 72 hr post compound treatment compound by half-leaf juice rubbing method2009Journal of agricultural and food chemistry, May-27, Volume: 57, Issue:10
Synthesis and biological activity evaluation of 1,2,3-thiadiazole derivatives as potential elicitors with highly systemic acquired resistance.
AID1092031Antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves exposed to 500 ug/mL for 20 min assessed as inhibition of viral growth measured 72 hr post compound treatment compound by half-leaf juice rubbing method2009Journal of agricultural and food chemistry, May-27, Volume: 57, Issue:10
Synthesis and biological activity evaluation of 1,2,3-thiadiazole derivatives as potential elicitors with highly systemic acquired resistance.
AID1082870Antiviral activity against Tobacco mosaic virus (TMV) assessed as inhibition effect at 500 ug/mL2012Journal of agricultural and food chemistry, Jun-13, Volume: 60, Issue:23
Design, synthesis, antiviral activity, and SARs of 14-aminophenanthroindolizidines.
AID1092014Induction of systemic acquired resistance against Tobacco mosaic virus (TMV) in tobacco plants exposed to 500 ug/mL compound through irrigation based soil treatment followed by 7 days culture under green house conditions assessed as inhibition of viral gr2009Journal of agricultural and food chemistry, May-27, Volume: 57, Issue:10
Synthesis and biological activity evaluation of 1,2,3-thiadiazole derivatives as potential elicitors with highly systemic acquired resistance.
AID1092192Antiviral activity against Tobacco mosaic virus (TMV) assessed as inhibition at 500 ug/mL2012Journal of agricultural and food chemistry, Oct-17, Volume: 60, Issue:41
Design, synthesis, and anti-tobacco mosaic virus (TMV) activity of phenanthroindolizidines and their analogues.
AID1092020Induction of systemic acquired resistance against Tobacco mosaic virus (TMV) in tobacco plants exposed to 500 ug/mL compound through leaf spray followed by 7 days culture under green house conditions assessed as inhibition of viral growth in leaves infect2009Journal of agricultural and food chemistry, May-27, Volume: 57, Issue:10
Synthesis and biological activity evaluation of 1,2,3-thiadiazole derivatives as potential elicitors with highly systemic acquired resistance.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (44.44)18.7374
1990's0 (0.00)18.2507
2000's2 (22.22)29.6817
2010's3 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]